GHK-Cu HSA/FSA Eligibility and Submission: Can You Use Pre-Tax Dollars?

What Is GHK-Cu and Why Does Regulatory Status Matter for HSA/FSA?

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) first isolated from human plasma. The body produces it endogenously, and serum concentrations decline with age. Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act can prepare GHK-Cu formulations, injectable, topical, or intranasal, when a licensed prescriber writes an individualized prescription.

503A Status and the FDA

Because GHK-Cu is not an FDA-approved finished drug product, it does not appear on the FDA's list of bulk drug substances currently under review for 503B outsourcing facilities in the same way that semaglutide does. The FDA's framework for 503A compounding permits preparation for individual patients when specific conditions are met, including a valid patient-specific prescription. FDA guidance on 503A compounding outlines the regulatory boundaries that distinguish individualized 503A preparations from mass-produced 503B products.

Why This Matters for Your HSA or FSA

HSA and FSA funds are governed by IRS Publication 502, which defines eligible medical expenses as amounts paid "for the diagnosis, cure, mitigation, treatment, or prevention of disease." A compounded drug prescribed for a diagnosed condition fits squarely in that definition. A peptide purchased over the counter for general anti-aging falls outside it. The distinction is legal, not pharmacological, and your plan administrator makes the final call. IRS Publication 502 (2024) lays out the full definition of qualifying medical expenses.

The IRS Section 213(d) Standard: What Actually Qualifies

Section 213(d) of the Internal Revenue Code is the legal backbone of every HSA and FSA eligibility decision. An expense qualifies when it is incurred "primarily for the prevention or alleviation of a physical or mental defect or illness." Cosmetic procedures, defined separately under Section 213(d)(9), do not qualify unless they correct a deformity arising from a congenital abnormality, personal injury, or disfiguring disease.

The Cosmetic Carve-Out

Topical GHK-Cu marketed purely for wrinkle reduction is cosmetic under the IRS definition and is not reimbursable. The same compound prescribed by a dermatologist or wound-care specialist for a diagnosed condition, chronic wound healing, post-surgical tissue repair, or a documented inflammatory skin disorder, shifts the classification. The prescription and the diagnosis code on the LMN are what change the legal category, not the molecule itself.

The "Primarily For" Test

IRS guidance requires that the primary purpose of the expenditure be medical care, not cosmetic enhancement or general well-being. A 2021 IRS FAQ update clarified that menstrual products and over-the-counter medications now qualify without a prescription under the CARES Act, but that update did not extend to prescription peptide compounds. IRS CARES Act HSA/FSA changes explains what changed and what did not.

Letter of Medical Necessity: The Document That Unlocks Reimbursement

A Letter of Medical Necessity (LMN) is a physician-authored document that connects a specific diagnosis to a specific treatment. For GHK-Cu, the LMN must accomplish four things to satisfy most plan administrators.

The Four-Part LMN Framework for GHK-Cu

1. Diagnosis with ICD-10 code. The letter must name the condition being treated. Relevant codes include L89 (pressure ulcer), L97 (non-pressure chronic ulcer), L98.4 (chronic ulcer of skin), or a dermatologist-documented inflammatory condition. Wound-care applications carry the strongest documentation history.

2. Therapeutic rationale. The physician explains why GHK-Cu is the chosen treatment over standard alternatives. Published research supports this: a 2018 review in Biomolecules documented GHK-Cu's role in stimulating wound healing through upregulation of collagen synthesis and anti-inflammatory signaling. Pickart L et al., Biomolecules 2018 provides the peer-reviewed basis a physician can reference.

3. Prescribing information. The letter must include the specific formulation, dose, frequency, and duration, for example, "GHK-Cu 0.1% topical cream, applied twice daily for 90 days."

4. Physician signature and NPI number. The plan administrator needs to verify that a licensed clinician issued the letter.

How Long the LMN Remains Valid

Most FSA and HSA plan administrators accept LMNs for a 12-month period. Some require annual renewal. A few large employers with self-insured plans accept multi-year LMNs for chronic conditions. Confirm the validity window with your plan before submitting.

Step-by-Step HSA/FSA Submission for GHK-Cu

Submitting a compounded peptide for reimbursement takes more documentation than submitting a generic antibiotic. The process has six practical steps.

Step 1: Obtain the Prescription and LMN Together

Ask your HealthRX prescriber to issue the LMN at the same time as the prescription. The two documents should share the same date and the same diagnosis code. Mismatched dates are one of the most common reasons plan administrators deny compounded-drug claims.

Step 2: Use a 503A-Licensed Pharmacy That Provides Itemized Receipts

Your receipt must show the drug name, National Drug Code (NDC) or pharmacy compounding identifier, the dispensing date, the prescriber's name, and the total cost. A credit-card statement alone is not sufficient. Reputable 503A pharmacies generate receipts that include all required fields automatically.

Step 3: Check Your Plan's Formulary Policy for Compounded Drugs

Not every HSA-compatible health plan, and almost no FSA, has a published formulary for compounded drugs. Instead, they apply the Section 213(d) standard case by case. Call the member-services line and ask specifically: "Does your plan reimburse 503A compounded peptides with an LMN?" Document the representative's name and the date of the call.

Step 4: Submit the Claim Packet

Most plans accept one of two submission routes. The first is a paper claim form mailed with copies of the prescription, LMN, and itemized receipt. The second is a portal upload through the plan's website or app. If your HSA is held at Fidelity, HSA Bank, or HealthEquity, the three largest custodians by assets as of 2025, all three support digital document uploads directly from the member dashboard.

Step 5: Respond to Requests for Additional Information

Plan administrators may ask for a written explanation from the prescribing physician or for clinical notes supporting the diagnosis. Turn these around within the plan's stated response window, usually 30 days. Failing to respond is treated as abandonment of the claim.

Step 6: Appeal Denied Claims

If the claim is denied, you have the right to a formal appeal under ERISA (for employer-sponsored FSAs) or under your HSA custodian's dispute process. The appeal should include the LMN, a copy of IRS Publication 502 citing the relevant section, and any published clinical evidence the prescriber provided. ERISA Section 503 appeals rights governs the employer-plan appeal pathway.

How GHK-Cu Is Priced and What Pre-Tax Savings Actually Look Like

GHK-Cu compounded at 503A pharmacies typically costs $80 to $220 per vial, depending on concentration (commonly 0.5 mg/mL to 5 mg/mL), volume, and the pharmacy's overhead. Topical formulations run $60 to $150 for a 30-day supply.

Calculating Your Real Savings

If you are in the 24% federal income tax bracket and pay an additional 5% state income tax, your effective marginal rate is 29%. Using $200 of pre-tax HSA dollars to pay for GHK-Cu saves $58 compared to paying out of pocket. Over a 12-month course at $150 per month, that is $522 in tax savings on $1,800 of compounded drug costs. The IRS 2025 HSA contribution limits allow individuals to contribute $4,300 and families to contribute $8,550, giving most patients ample pre-tax capacity to cover a full year of therapy.

FSA "Use It or Lose It" Planning

Standard health FSAs operate on a plan year with a forfeiture rule for unused balances. If your plan year ends December 31 and you start GHK-Cu therapy in October, confirm that you have enough remaining FSA balance and that your LMN covers the remainder of the plan year. Some employers offer a 2.5-month grace period or a $640 rollover (2025 IRS limit), which can extend your window.

What the Clinical Research Says About GHK-Cu

Understanding the published evidence helps your physician write a credible LMN and helps you understand what you are paying for.

Wound Healing and Tissue Repair

The strongest body of published evidence supports GHK-Cu's role in wound healing. A study indexed on PubMed demonstrated that GHK-Cu accelerates wound contraction and collagen deposition in animal models, with histological confirmation of improved dermal architecture. Pickart L, Margolina A. Rejuvenation Res. 2018 describes the peptide's mechanism across skin repair, anti-inflammatory action, and tissue remodeling.

Anti-Inflammatory Signaling

GHK-Cu modulates NF-kB signaling, reducing production of inflammatory cytokines including TNF-alpha and IL-6. A genomic analysis published in Genome Medicine found that GHK reverses the gene-expression patterns associated with aggressive cancer phenotypes and accelerated tissue aging. Pickart L et al., Genome Medicine 2012 provides the gene-expression dataset.

Collagen and Extracellular Matrix

Research published in Archives of Biochemistry and Biophysics confirmed that GHK-Cu stimulates synthesis of collagen, glycosaminoglycans, and decorin in human fibroblast cultures. Maquart FX et al., Arch Biochem Biophys 1993 is among the earliest peer-reviewed confirmations of this mechanism.

Taken together, these studies give a physician a reasonable evidence basis for writing an LMN when the clinical indication aligns with wound care, tissue repair, or documented inflammatory skin pathology.

Other Ways to Reduce GHK-Cu Costs in 2026

HSA and FSA reimbursement is the most tax-efficient route, but it is not the only one.

Membership and Subscription Programs

Some telehealth platforms, including HealthRX, bundle the prescriber consultation, LMN preparation, and pharmacy coordination into a single membership fee. The membership fee itself may qualify as a medical expense under Section 213(d) if it is structured as a telemedicine service rather than a general wellness subscription. Confirm the fee classification with your plan administrator before claiming it.

Comparing 503A Pharmacies

503A pharmacies set their own prices. The same GHK-Cu formulation can vary by 40% to 60% between pharmacies depending on overhead costs and compounding complexity. Asking your prescriber to send the prescription to two or three PCAB-accredited pharmacies for a price comparison is reasonable. PCAB (Pharmacy Compounding Accreditation Board) accreditation signals compliance with quality standards; the USP General Chapter 795 and 797 standards govern sterile and non-sterile compounding quality.

Bundling With Other Eligible Expenses

If you are paying for multiple compounded therapies, for example, GHK-Cu alongside a testosterone or thyroid compound, paying all of them through HSA funds multiplies the tax savings across the combined spend. Track each prescription separately for clean reimbursement records.

Risks of Incorrect HSA/FSA Claims

Using HSA or FSA funds for ineligible expenses carries real penalties. HSA disbursements for non-qualified expenses are subject to income tax plus a 20% excise tax if the account holder is under age 65. FSA overcharges typically require repayment to the plan. IRS Form 8889 instructions explain how qualified and non-qualified distributions are reported.

Submitting a claim with a fabricated or inaccurate LMN constitutes insurance fraud. The LMN must reflect a genuine clinical encounter and a real diagnosis. If you do not have a diagnosed condition that supports GHK-Cu therapy, the correct path is either to have a thorough evaluation that establishes one or to pay out of pocket.